Safety and immunogenicity of an inactivated severe acute respiratory syndrome coronavirus 2 vaccine in a subgroup of healthy adults in Chile
…, C Covián, D Moreno-Tapia… - Clinical Infectious …, 2022 - academic.oup.com
Background The development of effective vaccines against coronavirus disease 2019 is a
global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (…
global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (…
[HTML][HTML] Recognition of variants of concern by antibodies and T cells induced by a SARS-CoV-2 inactivated vaccine
…, Y Vázquez, D Rivera-Pérez, D Moreno-Tapia… - Frontiers in …, 2021 - frontiersin.org
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus
responsible of the current pandemic ongoing all around the world. Since its discovery in 2019, …
responsible of the current pandemic ongoing all around the world. Since its discovery in 2019, …
A booster dose of CoronaVac increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern
…, RV Berríos-Rojas, LA González, D Moreno-Tapia… - MBio, 2022 - Am Soc Microbiol
CoronaVac is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization
(WHO). Previous studies reported increased levels of neutralizing antibodies and specific …
(WHO). Previous studies reported increased levels of neutralizing antibodies and specific …
[HTML][HTML] Interim report: Safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial
…, G Canedo-Marroquín, C Covián, D Moreno-Tapia… - MedRxiv, 2021 - ncbi.nlm.nih.gov
Background The ongoing COVID-19 pandemic has had a significant impact worldwide, with
an incommensurable social and economic burden. The rapid development of safe and …
an incommensurable social and economic burden. The rapid development of safe and …
[HTML][HTML] Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine
…, D Rivera-Pérez, D Moreno-Tapia… - Frontiers in …, 2021 - frontiersin.org
Constant efforts to prevent infections by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
are actively carried out around the world. Several vaccines are currently …
are actively carried out around the world. Several vaccines are currently …
Inactivated vaccine-induced SARS-CoV-2 variant-specific immunity in children
Multiple vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
have been evaluated in clinical trials. However, trials addressing the immune response in the …
have been evaluated in clinical trials. However, trials addressing the immune response in the …
[HTML][HTML] Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adults
Background The Omicron variant has challenged the control of the COVID-19 pandemic
due to its immuno-evasive properties. The administration of a booster dose of a SARS-CoV-2 …
due to its immuno-evasive properties. The administration of a booster dose of a SARS-CoV-2 …
Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial
Background: The development of vaccines to control the coronavirus disease 2019 (COVID-19)
pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute …
pandemic progression is a worldwide priority. CoronaVac is an inactivated severe acute …
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize delta and omicron variants of concern
…, RV Berríos-Rojas, LA González, D Moreno-Tapia… - medRxiv, 2021 - medrxiv.org
Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-19.
CoronaVac® is an inactivated SARS-CoV-2 vaccine approved by the World Health …
CoronaVac® is an inactivated SARS-CoV-2 vaccine approved by the World Health …
[HTML][HTML] Limited Heme Oxygenase Contribution to Modulating the Severity of Salmonella enterica serovar Typhimurium Infection
VP Sebastián, D Moreno-Tapia, F Melo-González… - Antioxidants, 2022 - mdpi.com
An important virulence trait of Salmonella enterica serovar Typhimurium (S. Typhimurium) is
the ability to avoid the host immune response, generating systemic and persistent infections. …
the ability to avoid the host immune response, generating systemic and persistent infections. …
